Aclaris Therapeutics, Inc.
ACRS
$3.59
$0.298.79%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 7.83M | 15.74M | 16.79M | 17.78M | 18.72M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 7.83M | 15.74M | 16.79M | 17.78M | 18.72M |
| Cost of Revenue | 62.22M | 61.43M | 54.16M | 51.53M | 50.11M |
| Gross Profit | -54.39M | -45.69M | -37.37M | -33.75M | -31.39M |
| SG&A Expenses | 21.97M | 21.35M | 22.13M | 21.50M | 22.20M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 81.90M | 81.55M | 75.22M | 71.96M | 71.25M |
| Operating Income | -74.08M | -65.81M | -58.43M | -54.18M | -52.53M |
| Income Before Tax | -64.92M | -141.68M | -134.65M | -130.21M | -132.07M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -64.92 | -141.68 | -134.65 | -130.21 | -132.07 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -64.92M | -141.68M | -134.65M | -130.21M | -132.07M |
| EBIT | -74.08M | -65.81M | -58.43M | -54.18M | -52.53M |
| EBITDA | -74.00M | -65.70M | -58.26M | -53.99M | -52.22M |
| EPS Basic | -0.53 | -1.38 | -1.37 | -1.40 | -1.51 |
| Normalized Basic EPS | -0.32 | -0.29 | -0.28 | -0.30 | -0.35 |
| EPS Diluted | -0.53 | -1.38 | -1.37 | -1.40 | -1.51 |
| Normalized Diluted EPS | -0.32 | -0.29 | -0.28 | -0.30 | -0.35 |
| Average Basic Shares Outstanding | 490.26M | 462.90M | 411.66M | 360.37M | 309.05M |
| Average Diluted Shares Outstanding | 490.26M | 462.90M | 411.66M | 360.37M | 309.05M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |